Race and cause specific survival with prostate cancer: Influence of clinical stage, Gleason score, age and treatment

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 137-142

  Fowler Jr , Jackson E ^a   Bigler, Steven A ^a   Bowman, Gail ^a   Kilambi, Nirmal K ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Prostatic neoplasms; Race; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RACE DIFFERENCE; SCORING SYSTEM;

EID: 0033992032     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67989-X     Document Type: Article

References (27)

1. Wingo, P. A., Bolden, S., Tong, T. et al: Cancer statistics for African-Americans. CA Cancer J Clin, 46: 113, 1996.
2. Miller, B. A., Gloeckler Ries, L. A., Hankey, B. F. et al: SEER Cancer Statistics Review, 1973-1990. Baltimore: National Institutes of Health, 1993.
3. Moul, J. W., Sesterhenn, I. A., Connelly, R. R. et al: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA, 274: 1277, 1995.
4. Fowler, J. E., Jr. and Bigler, S. A.: A prospective study of serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma. Cancer, 86: 836, 1999.
5. Vijayakumar, S., Karrison, T., Weichselbaum, R. R. et al: Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev, 1: 541, 1992.
6. Pienta, K. J., Demers, R., Hoff, M. et al: Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology, 45: 93, 1995.
7. Powell, I. J., Schwartz, K. and Hussain, M.: Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology, 46: 825, 1995.
8. Brawn, P. N., Johnson, E. H., Kuhl, D. L. et al: Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer, 71: 2569, 1993.
9. Optenberg, S. A., Thompson, I. M., Friedrichs, P. et al: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA, 274: 1599, 1995.
10. Lepor, H., Kimball, A. W. and Walsh, P. C.: Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol, 141: 82, 1989.
11. Wingo, P. A. Landis, S. and Ries, L. A. G.: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin, 47: 239, 1997.
12. Beahrs, O. H., Henson, D. E., Hutter, R. V. et al: Manual for Staging of Cancer, 4th ed. Philadelphia: J. B. Lippincott, 1992.
13. Gleason, D. F.: Classification of prostatic carcinomas. Cancer Chemother Rep, 50: 125, 1966.
14. National Center for Health Statistics: Vital Statistics of the United States, 1990. Washington: Public Health Service, vol. II, mortality, part A, pp. 8-9, 1994.
15. Steinberg, D. M., Sauvageot, J., Piantadosi, S. et al: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol, 21: 566, 1997.
16. Albertsen, P. C., Hanley, J. A., Gleason D. F. et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280: 975, 1998.
17. Pound, C. R., Partin, A. W., Epstein, J. I. et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am, 24: 395, 1997.
18. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer, 79: 1370, 1997.
19. Iselin, C. E., Box, J. W., Vollmer, R. T. et al: Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer, 83: 2353, 1998.
20. Roach, M., III, Lu, J., Pilepich, M. V. et al: Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol, 161: 864, 1999.
21. Fowler, J. E., Jr., and Terrell, F.: Survival in blacks and whites after treatment for localized prostate cancer. J Urol, 156: 133, 1996.
22. Harlin, L., Brawley, O., Pommerenke, F. et al: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol, 13: 93, 1995.
23. Mettlin, C. J., Murphy, G. P., McGinnis, L. S. et al: The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer, 76: 1104, 1995.
24. Fisher, E. S. and Welch, H. G.: The future of the Department of Veterans Affairs health care system. JAMA, 273: 651, 1995.
25. Potosky, A. L., Miller, B. A., Albertsen, P. C. et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA, 273: 548, 1995.
26. Schwartz, K. L., Severson, R. K., Gurney, J. G. et al: Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area 1973-1994. Cancer, 78: 1260, 1996.
27. Stephenson, R. A.: Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology and End Results (SEER) Program. Monogr Urol, 19: 3, 1998.